查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1867161

巨細胞病毒治療市場按治療類型、給藥途徑、最終用戶、通路和患者類型分類－2025-2032年全球預測

Cytomegalovirus Treatment Market by Treatment Type, Route Of Administration, End User, Distribution Channel, Patient Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，巨細胞病毒治療市場將成長至 10.6571 億美元，複合年成長率為 7.97%。

關鍵市場統計數據
基準年 2024 5.7699億美元
預計年份：2025年 6.24億美元
預測年份 2032 10.6571億美元
複合年成長率 (%) 7.97%

將不斷發展的鉅巨細胞病毒治療模式置於新治療方法、診斷技術和臨床實踐的運作要務之中。

巨細胞病毒(CMV) 管理的臨床和商業性層面正迅速發展，這主要得益於治療方法、診斷技術和診療路徑的進步。這些進步正在重塑臨床醫生預防、檢測和治療CMV的方式。傳統上，CMV的治療依賴於有限的抗病毒藥物選擇以及基於臨床症狀和常規PCR監測的被動治療策略。然而，在過去十年中，高風險環境下的預防措施、病毒量監測的改進以及新型作用機制的出現，都為治療決策增添了更多複雜性。

新型抗病毒藥物、精準診斷技術和整合式診療路徑如何融合，重塑巨細胞病毒的治療與臨床決策

巨細胞病毒(CMV) 的治療格局正在經歷變革性變化，重新定義了治療標準，並挑戰了長期以來的臨床範式。這項變革的核心在於具有全新作用機制的藥物的出現，這些藥物拓展了治療選擇，超越了傳統的 DNA聚合酵素抑制劑，從而能夠針對抗藥性和難治性性行為感染進行標靶治療。同時，預防策略，尤其是在移植患者等高風險族群中，也日益受到關注，因為越來越多的證據表明，預防策略具有預防臨床顯著疾病和降低後續發病率的潛力。

評估2025年美國新關稅趨勢對鉅細胞病毒（CMV）治療和診斷採購、供應鏈韌性和成本管理策略的影響

2025年，美國關稅政策和貿易措施的變化對整個醫藥和診斷供應鏈產生了連鎖反應，直接影響巨細胞病毒治療生態系統。對某些進口活性藥物原料藥、製劑和特殊診斷劑提高關稅，增加了依賴全球採購的相關人員的現場成本。為此，製造商和經銷商採取措施，重新評估供應契約，加快對替代供應商的資格認證，並考慮將一些關鍵的生產活動遷回國內。

策略性細分洞察，包括對治療目標、給藥途徑、醫療機構、通路和患者群體的詳細分析，對於制定有針對性的決策至關重要。

深入了解患者群體、醫療機構和通路對於最佳化巨細胞病毒）領域的臨床和商業策略至關重要。根據治療類型，市場可分為「治療性」與「預防性」兩大類，分別對應不同的臨床目標。治療方法旨在抑制病毒複製並消除疾病，而預防策略則旨在預防易感人群發生CMV感染。在這些治療目標之間轉換需要臨床醫生、實驗室和藥房之間的密切合作，以確保最佳的用藥時間和劑量。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 擴大來特莫韋預防性用藥範圍，以降低造血幹細胞移植受者鉅細胞病毒重新運作的風險
  • 馬立巴韋療法的進展表明，其對移植受者難治性或抗藥性鉅細胞感染疾病有效。
  • 開發和臨床評估一種新型鉅細胞病毒疫苗，用於預防孕婦先天性巨細胞病毒
  • 推動抗病毒抗藥性檢測方法的發展，有助於為鉅細胞病毒感染患者制定個人化的預防性治療策略。
  • 綜合分析真實世界證據研究，評估新興鉅細胞病毒治療方法的長期安全性和成本效益
  • 生技公司與製藥公司夥伴關係加速新型鉅細胞病毒單株抗體療法的研發
  • 針對具有高度未滿足需求的鉅細胞病毒治療候選藥物，簡審類和孤兒藥認定方面的監管進展
  • 推出照護現場鉅細胞病毒量檢測方案，以最佳化免疫力缺乏患者的早期診斷和介入。
  • 市場進入挑戰和定價談判影響下一代鉅細胞病毒抗病毒藥物的報銷途徑
  • 基於RNA的疫苗平台在廣譜巨細胞病毒免疫策略的進展

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章巨細胞病毒病毒治療市場（依治療方式分類）

  • 治療
  • 預防

第9章巨細胞病毒治療市場（依給藥途徑分類）

  • 靜脈注射
  • 口服
  • 局部用藥

第10章巨細胞病毒治療市場（依最終用戶分類）

  • 門診治療中心
  • 診所
  • 醫院
    • 二級醫療機構
    • 三級醫療機構

第11章巨細胞病毒分銷管道分類）

  • 醫院藥房
    • 本地部署
    • 第三方物流
  • 網路藥房
  • 零售藥房
    • 鏈
    • 獨立的

第12章 依患者類型分類的巨細胞病毒治療市場

  • 成人版
  • 新生
  • 孩子們
    • 青春期
    • 嬰兒

第13章巨細胞病毒治療市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章巨細胞病毒治療市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國巨細胞病毒治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • F. Hoffmann-La Roche Ltd
    • Merck & Co., Inc.
    • Gilead Sciences, Inc.
    • Takeda Pharmaceutical Company Limited
    • CSL Behring AG
    • Chimerix, Inc.
    • VBI Vaccines Inc.
Product Code: MRR-7949F05839D1

The Cytomegalovirus Treatment Market is projected to grow by USD 1,065.71 million at a CAGR of 7.97% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 576.99 million
Estimated Year [2025] USD 624.00 million
Forecast Year [2032] USD 1,065.71 million
CAGR (%) 7.97%

Contextualizing the evolving Cytomegalovirus treatment paradigm amid new therapeutics, diagnostics, and operational imperatives in clinical practice

The clinical and commercial contours of Cytomegalovirus management are evolving rapidly, driven by advances in therapeutics, diagnostics, and care pathways that together reshape how clinicians approach prevention, detection, and treatment. Historically, CMV care relied on a small set of antiviral agents and reactive treatment strategies guided by clinical symptoms and routine PCR monitoring. Over the past decade, however, prophylactic approaches in high-risk settings, improved viral load surveillance, and the advent of novel mechanisms of action have introduced greater nuance into therapeutic decision-making.

Consequently, stakeholders across the continuum - from transplant clinicians and neonatologists to hospital pharmacy directors and diagnostic laboratories - face new choices about when to deploy prophylaxis, how to interpret molecular diagnostics, and how to manage drug-resistant infections. These clinical decisions are paralleled by shifts in operational priorities: supply chain resilience, formulary management, and patient access programs now factor prominently into strategy discussions. As a result, organizations must synthesize clinical evidence, regulatory developments, and operational realities to craft integrated responses that maintain patient safety while optimizing resource allocation.

This executive summary distills contemporary developments in CMV treatment, highlights transformative shifts in therapeutics and diagnostics, and outlines practical implications for segmentation, regional priorities, competitive dynamics, and strategic action. The objective is to provide a clear, actionable foundation for leaders tasked with navigating an increasingly complex landscape where clinical innovation and operational execution intersect.

How novel antivirals, precision diagnostics, and integrated care pathways are converging to reshape Cytomegalovirus management and clinical decision-making

The treatment landscape for Cytomegalovirus has undergone transformative shifts that are redefining standards of care and challenging long-standing clinical paradigms. At the core of this transformation is the arrival of agents with novel mechanisms of action that expand therapeutic options beyond classical DNA polymerase inhibitors, enabling targeted approaches for resistant and refractory infections. Simultaneously, prophylactic strategies in high-risk populations, particularly among transplant recipients, have gained traction as evidence demonstrates potential to prevent clinically significant disease and reduce downstream morbidity.

Parallel to pharmaceutical innovation, diagnostics have become more sophisticated and central to care pathways. Quantitative PCR assays, standardized viral load thresholds, and next-generation sequencing for resistance profiling are increasingly used to personalize therapy and distinguish between viral replication and clinically relevant disease. As a result, clinicians are moving from empiric, symptom-driven treatment toward preemptive and data-driven interventions that can reduce overtreatment and better manage resistance emergence.

Operationally, these clinical shifts have prompted healthcare systems to reevaluate pharmacy procurement, inventory strategies, and laboratory capacity. There is growing emphasis on integrated care models that align transplant programs, infectious disease teams, and ambulatory providers around shared monitoring protocols. Moreover, policy and reimbursement environments are adapting to accommodate prophylactic indications and innovative agents, with payers seeking robust real-world evidence to justify broader coverage. In combination, these trends create both opportunity and complexity for manufacturers, providers, and payers as they navigate a landscape defined by clinical innovation and heightened expectations for patient outcomes.

Assessing how new United States tariff dynamics in 2025 have affected procurement, supply chain resilience, and cost-management strategies for CMV therapeutics and diagnostics

In 2025, changes to tariff policies and trade measures in the United States created ripple effects across the pharmaceutical and diagnostics supply chain that bear directly on the Cytomegalovirus treatment ecosystem. Increased duties on certain imported active pharmaceutical ingredients, finished dosage forms, and specialized diagnostic reagents elevated landed costs for stakeholders that rely on global sourcing. Manufacturers and distributors responded by re-evaluating supply contracts, accelerating qualification of alternative suppliers, and considering partial reshoring of critical manufacturing activities.

These adjustments prompted hospital pharmacies and procuring entities to review inventory strategies and procurement terms to mitigate exposure to price volatility and delivery delays. In parallel, some diagnostic laboratories accelerated adoption of domestic reagent suppliers or invested in in-house assay development to reduce reliance on constrained import channels. As a transitional measure, healthcare systems prioritized continuity of care for high-risk patients by creating buffer stocks and negotiating multi-year supply agreements with manufacturers willing to absorb tariff-related cost fluctuations.

Longer-term implications include a renewed focus on supply chain resilience and supplier diversification. Contracting practices evolved to include tariff-contingent clauses and collaborative risk-sharing arrangements. Regulatory and procurement teams increasingly collaborated to fast-track local regulatory approvals for alternatives and to harmonize quality standards across tiers of suppliers. Collectively, these adaptive measures reduced near-term disruption and established more robust frameworks for ensuring uninterrupted access to both antivirals and diagnostic reagents.

Strategic segmentation insights detailing treatment goals, administration routes, care settings, distribution pathways, and patient cohorts for focused decision-making

A granular understanding of patient populations, care settings, and distribution pathways is essential for tailoring clinical and commercial strategies within the Cytomegalovirus domain. Based on Treatment Type, the market is studied across Curative and Prophylaxis, reflecting distinct clinical objectives: curative regimens aim to suppress active replication and resolve disease, while prophylactic strategies seek to prevent CMV disease in vulnerable cohorts. Transitioning between these treatment goals requires alignment between clinicians, laboratory services, and pharmacy operations to ensure timing and dosing are optimized.

Based on Route Of Administration, the market is studied across Intravenous, Oral, and Topical, each of which carries practical implications for inpatient management, outpatient adherence, and formulation development. Intravenous therapies remain central in severe or hospitalized cases, whereas oral agents enable outpatient management and prophylaxis programs, and topical options-while limited-address localized manifestations. This distribution of routes shapes procurement priorities, patient education efforts, and therapeutic adherence initiatives.

Based on End User, the market is studied across Ambulatory Care Centers, Clinics, and Hospitals. The Hospitals is further studied across Secondary and Tertiary, highlighting differential capabilities: tertiary centers concentrate advanced transplant services and complex case management, while secondary hospitals manage common inpatient care and follow-up. These distinctions influence where specialized diagnostics and advanced antiviral agents are primarily utilized, and they inform strategic outreach and educational efforts.

Based on Distribution Channel, the market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy. The Hospital Pharmacy is further studied across On-Premise and Third-Party Logistics, reflecting variations in inventory control and fulfillment models. The Retail Pharmacy is further studied across Chain and Independent, which affects patient access, dispensing consistency, and adherence support. Finally, based on Patient Type, the market is studied across Adult, Neonatal, and Pediatric. The Pediatric is further studied across Adolescent and Infant, underscoring differences in dosing, monitoring, and clinical presentation that require age-appropriate formulations and specialized clinical pathways.

How regional clinical capacity, regulatory heterogeneity, and manufacturing trends are directing differentiated CMV treatment strategies across global markets

Regional differences exert a powerful influence on clinical practice, regulatory priorities, and supply chain strategies for CMV treatment, making geographic insight essential for tailored planning. In the Americas, concentrated clinical expertise, high transplant volumes, and active adoption of novel therapeutics and diagnostics create an environment conducive to rapid uptake of prophylactic strategies and advanced resistance testing. Health systems in the region are also sensitive to procurement cycles and reimbursement frameworks, which directly affect how new agents are integrated into formularies and care pathways.

In Europe, Middle East & Africa, regulatory heterogeneity and variable healthcare infrastructure shape differentiated access to advanced CMV therapies and diagnostics. Some markets prioritize centralized testing and specialist-led prophylaxis programs, while others face resource constraints that limit widespread adoption. Policymakers in these regions often emphasize equitable access and cost-effectiveness, prompting manufacturers to pursue tailored pricing strategies and real-world evidence generation to support broader coverage.

Across Asia-Pacific, increasing transplant activity, expanding diagnostic capacity, and growing pharmaceutical manufacturing capabilities create a dynamic environment for CMV innovation. Many countries in the region are investing in laboratory infrastructure and bolstering in-country production to reduce import dependence. At the same time, divergent regulatory pathways and reimbursement environments necessitate region-specific launch strategies and localized clinical evidence to support uptake. Combined, these regional nuances compel stakeholders to design differentiated engagement plans that reflect clinical need, system capacity, and payer expectations.

Competitive and collaborative company strategies emphasizing clinical evidence, diagnostic integration, and supply chain resilience in CMV treatment development

Competitive dynamics within the Cytomegalovirus treatment ecosystem reflect a mix of established pharmaceutical players, emerging biotech innovators, and specialized diagnostics providers, each pursuing strategies that emphasize clinical differentiation and operational resilience. Established firms have focused on lifecycle management and defending prophylactic and therapeutic indications through additional evidence generation and real-world studies. At the same time, newer entrants and biotech companies emphasize novel mechanisms of action, smaller-molecule platforms targeting resistance pathways, and biologic approaches such as cell therapies and antibody-based prophylaxis.

Diagnostics firms and laboratory networks are concurrently advancing assays for quantitative viral load monitoring and resistance detection, seeking to integrate these capabilities into clinician workflows and electronic health records. Partnerships between therapeutics developers and diagnostics providers are increasingly common, intended to create bundled solutions that link molecular diagnostics to treatment decision algorithms. Supply chain collaboration has also become more strategic, with manufacturers diversifying sourcing and investing in regional manufacturing to reduce exposure to tariff and logistics disruptions. Overall, corporate strategies that blend robust clinical evidence, diagnostic integration, and resilient manufacturing are most likely to secure durable adoption in complex care settings.

Practical, high-priority actions for leaders to accelerate adoption of effective CMV therapies while strengthening supply chains and payer engagement

Industry leaders should pursue a coordinated set of actions that accelerate adoption of clinically meaningful innovations while safeguarding access and affordability. First, prioritize development and clinical validation of oral agents and prophylactic regimens that reduce hospitalization and enable outpatient management, since such options improve patient convenience and relieve inpatient resource pressures. Simultaneously, invest in companion diagnostics and standardized viral load thresholds to support preemptive treatment algorithms and to reduce inappropriate use of broad-spectrum antivirals.

Second, build supply chain resilience by diversifying raw material sources, qualifying backup suppliers for critical reagents, and exploring regional manufacturing partnerships to mitigate tariff exposure and logistical disruption. Third, generate robust real-world evidence and health economic data to demonstrate value in prophylactic indications and to support negotiations with payers. Fourth, design patient-centered adherence programs and formulary support that account for differences in route of administration and care settings, thereby improving outcomes across adult, neonatal, and pediatric populations. Finally, engage proactively with regulators, transplant networks, and laboratory consortia to harmonize standards for resistance testing and to accelerate adoption of best-practice monitoring protocols. Together, these actions can align clinical benefit with operational feasibility and payer acceptance.

Transparent mixed-methods research approach integrating clinical literature, expert interviews, and regulatory review to generate actionable CMV treatment intelligence

The research underpinning this report was constructed using a mixed-methods approach that triangulates clinical, regulatory, and operational data to ensure robust insights. Secondary research included a comprehensive review of peer-reviewed clinical literature, regulatory approval documents, clinical trial registries, and guideline statements from leading transplant and infectious disease societies. This foundation informed identification of key therapeutic agents, diagnostic modalities, and emerging clinical practices.

Primary research supplemented these findings through structured interviews with subject-matter experts, including transplant physicians, infectious disease specialists, hospital pharmacy directors, diagnostic laboratory leaders, and supply chain managers. These conversations provided contextual understanding of implementation barriers, real-world clinical decision pathways, and procurement practices. Data synthesis prioritized consistency across sources and emphasized transparency in methodology, with cross-validation performed through multiple independent inputs. Quality assurance processes included peer review by clinical experts and methodologists to ensure analytical rigor and relevance to decision-makers.

Summarizing the imperative to align therapeutic innovation, diagnostic precision, and supply chain resilience to improve outcomes in CMV care

The Cytomegalovirus treatment space is at an inflection point where therapeutic innovation, diagnostic precision, and operational resilience converge to reshape patient care. As novel antivirals and prophylactic strategies move into practice, they bring the promise of reduced morbidity in vulnerable populations alongside the challenge of integrating new protocols into complex care ecosystems. Diagnostics will play a central role in enabling targeted, preemptive interventions, while supply chain and procurement strategies must evolve to ensure uninterrupted access to essential therapies and reagents.

For stakeholders, the imperative is to act decisively: align clinical protocols with diagnostic capabilities, invest in evidence generation that demonstrates real-world value, and shore up supply chains against geopolitical and tariff-driven disruptions. By doing so, providers, manufacturers, and payers can collectively improve outcomes for transplant recipients, neonates, and other high-risk cohorts while maintaining operational and financial sustainability. The path forward benefits from collaboration across clinical, commercial, and policy domains to translate scientific progress into accessible, reliable care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growing adoption of letermovir prophylaxis in hematopoietic stem cell transplant recipients to reduce CMV reactivation risk
  • 5.2. Advancements in maribavir therapy demonstrating efficacy in refractory or resistant CMV infections among transplant patients
  • 5.3. Development and clinical evaluation of novel CMV vaccines targeting congenital cytomegalovirus prevention in pregnant women
  • 5.4. Emergence of antiviral resistance detection assays driving personalized preemptive therapy strategies for CMV-infected patients
  • 5.5. Integration of real-world evidence studies to assess long-term safety and cost-effectiveness of emerging CMV treatments
  • 5.6. Collaborative partnerships between biotech and pharmaceutical companies accelerating novel CMV monoclonal antibody therapies
  • 5.7. Regulatory progress in fast track and orphan drug designation for investigational CMV therapeutics addressing high unmet need
  • 5.8. Implementation of point-of-care CMV viral load testing solutions to optimize early diagnosis and intervention in immunocompromised hosts
  • 5.9. Market access challenges and pricing negotiations influencing reimbursement pathways for next-generation CMV antivirals
  • 5.10. Advances in RNA-based vaccine platforms showing promise for broad-spectrum cytomegalovirus immunization strategies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cytomegalovirus Treatment Market, by Treatment Type

  • 8.1. Curative
  • 8.2. Prophylaxis

9. Cytomegalovirus Treatment Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral
  • 9.3. Topical

10. Cytomegalovirus Treatment Market, by End User

  • 10.1. Ambulatory Care Centers
  • 10.2. Clinics
  • 10.3. Hospitals
    • 10.3.1. Secondary
    • 10.3.2. Tertiary

11. Cytomegalovirus Treatment Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
    • 11.1.1. On-Premise
    • 11.1.2. Third-Party Logistics
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy
    • 11.3.1. Chain
    • 11.3.2. Independent

12. Cytomegalovirus Treatment Market, by Patient Type

  • 12.1. Adult
  • 12.2. Neonatal
  • 12.3. Pediatric
    • 12.3.1. Adolescent
    • 12.3.2. Infant

13. Cytomegalovirus Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cytomegalovirus Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cytomegalovirus Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. F. Hoffmann-La Roche Ltd
    • 16.3.2. Merck & Co., Inc.
    • 16.3.3. Gilead Sciences, Inc.
    • 16.3.4. Takeda Pharmaceutical Company Limited
    • 16.3.5. CSL Behring AG
    • 16.3.6. Chimerix, Inc.
    • 16.3.7. VBI Vaccines Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. CYTOMEGALOVIRUS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. CYTOMEGALOVIRUS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CYTOMEGALOVIRUS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY CURATIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY CURATIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY CURATIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY CURATIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY CURATIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY CURATIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PROPHYLAXIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PROPHYLAXIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PROPHYLAXIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PROPHYLAXIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY SECONDARY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY SECONDARY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY SECONDARY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY SECONDARY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY SECONDARY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY SECONDARY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY TERTIARY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY TERTIARY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY TERTIARY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY TERTIARY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY TERTIARY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY TERTIARY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ON-PREMISE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ON-PREMISE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ON-PREMISE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ON-PREMISE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ON-PREMISE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ON-PREMISE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY THIRD-PARTY LOGISTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY THIRD-PARTY LOGISTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY THIRD-PARTY LOGISTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY THIRD-PARTY LOGISTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY THIRD-PARTY LOGISTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY THIRD-PARTY LOGISTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY CHAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY CHAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY CHAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY CHAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY CHAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY CHAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY INDEPENDENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY INDEPENDENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY INDEPENDENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY INDEPENDENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY INDEPENDENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY INDEPENDENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY NEONATAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY NEONATAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY NEONATAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY NEONATAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY NEONATAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY NEONATAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ADOLESCENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ADOLESCENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ADOLESCENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ADOLESCENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ADOLESCENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY INFANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY INFANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY INFANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY INFANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY INFANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY INFANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, 2025-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. MIDDLE EAST CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. MIDDLE EAST CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 262. MIDDLE EAST CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. MIDDLE EAST CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 266. MIDDLE EAST CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 268. MIDDLE EAST CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, 2025-2032 (USD MILLION)
  • TABLE 277. AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 282. AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 283. AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 284. AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 285. AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 286. AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 287. AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 288. AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 289. AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 290. AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 291. AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 292. AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 293. AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 295. AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
  • TABLE 296. AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, 2025-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 300. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 301. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 302. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 305. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 306. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 307. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 308. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 311. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 312. ASIA-PACIFIC CYTOMEGALOVIRUS TREATME